Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats
- PMID: 10690286
- DOI: 10.1016/s0008-6363(99)00254-0
Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats
Abstract
Objective: We examined the effect of the suppression of plasma angiotensinogen (AGT) by the intravenous injection of antisense oligodeoxynucleotides (ODNs) against AGT targeted to the liver on cardiac remodeling in spontaneously hypertensive rats (SHR). The ODNs against rat AGT were coupled to asialoglycoprotein (ASOR) carrier molecules, which serve as an important method for regulating liver gene expression.
Methods: Male SHR (n = 18), and age-matched male Wistar-Kyoto rats (WKY, n = 6) were used for this study. At 10 weeks of age, the SHR were divided into three groups (each group n = 6), and the systolic blood pressure (SBP) did not significantly change among them. The control SHR and WKY groups received saline, the sense SHR group was injected with the sense ODNs complex and the antisense SHR group was injected with the antisense ODNs complex, from 10 to 20 weeks of age. ASOR-poly(L)lysine-ODNs complex was injected via the tail veins twice a week.
Results: At the end of the treatment, a reduction of hepatic AGT mRNA, cardiac angiotensin II type 1 receptor mRNA and the plasma AGT concentration was only observed in the antisense-injected SHR but not in the other groups of SHR and WKY. This antisense therapy did not significantly change the mRNA expression for angiotensin converting enzyme, angiotensin II type 2 receptor and AGT in the left ventricle (LV) among all three groups. Although the plasma angiotensin II (Ang II) concentration significantly decreased to the level of WKY after the antisense therapy, the SBP, LV to body weight ratio and % collagen volume fraction also showed a reduction, however, these findings were still larger than in the WKY than in either the sense-injected SHR or control SHR.
Conclusion: The plasma AGT is considered to play a role in the development of cardiac hypertrophy in SHR, but it has not a complete effects on cardiac remodeling even if the plasma Ang II levels are inhibited because of an insufficient suppression of hypertension.
Similar articles
-
Reduction of plasma angiotensin II to normal levels by antisense oligodeoxynucleotides against liver angiotensinogen cannot completely attenuate vascular remodeling in spontaneously hypertensive rats.J Hypertens. 2000 Jun;18(6):725-31. doi: 10.1097/00004872-200018060-00010. J Hypertens. 2000. PMID: 10872557
-
Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats.Hypertension. 1998 May;31(5):1166-70. doi: 10.1161/01.hyp.31.5.1166. Hypertension. 1998. PMID: 9576130
-
Nanoparticle-mediated RNA interference of angiotensinogen decreases blood pressure and improves myocardial remodeling in spontaneously hypertensive rats.Mol Med Rep. 2015 Sep;12(3):4657-4663. doi: 10.3892/mmr.2015.3909. Epub 2015 Jun 11. Mol Med Rep. 2015. PMID: 26062941
-
Gene therapy for hypertension: sense and antisense strategies.Expert Opin Biol Ther. 2001 Jul;1(4):655-62. doi: 10.1517/14712598.1.4.655. Expert Opin Biol Ther. 2001. PMID: 11727501 Review.
-
Somatic gene therapy for hypertension.Braz J Med Biol Res. 2000 Jun;33(6):715-21. doi: 10.1590/s0100-879x2000000600013. Braz J Med Biol Res. 2000. PMID: 10829100 Review.
Cited by
-
Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.Biosci Rep. 2019 Jan 11;39(1):BSR20180201. doi: 10.1042/BSR20180201. Print 2019 Jan 31. Biosci Rep. 2019. PMID: 30530571 Free PMC article. Review.
-
Angiotensin AT2 receptors: cardiovascular hope or hype?Br J Pharmacol. 2003 Nov;140(5):809-24. doi: 10.1038/sj.bjp.0705448. Epub 2003 Oct 6. Br J Pharmacol. 2003. PMID: 14530223 Free PMC article. Review. No abstract available.
-
Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.Pharmacol Res. 2017 Nov;125(Pt A):57-71. doi: 10.1016/j.phrs.2017.05.020. Epub 2017 May 29. Pharmacol Res. 2017. PMID: 28571891 Free PMC article. Review.
-
CRISPR/Cas9 Mediated Deletion of the Angiotensinogen Gene Reduces Hypertension: A Potential for Cure?Hypertension. 2021 Jun;77(6):1990-2000. doi: 10.1161/HYPERTENSIONAHA.120.16870. Epub 2021 Apr 5. Hypertension. 2021. PMID: 33813849 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous